Letter to the EditorRe: Stefano Fanti, Alberto Briganti, Louise Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5:530–6: Extended Use of PSMA PET/CT in Candidates for Focal Therapy
References (9)
- et al.
Focal therapy meets prostate cancer
Lancet
(2010) - et al.
68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study
J Urol
(2018) - et al.
Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis
Eur Urol Focus
(2021) - et al.
The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study
Eur Urol
(2021)
There are more references available in the full text version of this article.
Cited by (0)
© 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.